Skip to main content

Drug Interactions between palifermin and Vyxeos

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DAUNOrubicin liposomal cytarabine liposomal

Applies to: Vyxeos (cytarabine liposomal / daunorubicin liposomal) and Vyxeos (cytarabine liposomal / daunorubicin liposomal)

MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow, gastrointestinal tract and heart.

MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.

References

  1. (2001) "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb
  2. (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
  3. (2022) "Product Information. Fluorouracil (fluorouracil)." Roche Laboratories
  4. (2001) "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn
  5. (2001) "Product Information. Ellence (epirubicin)." Pharmacia and Upjohn
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  7. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
  8. Cerner Multum, Inc. "Australian Product Information."
  9. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
View all 9 references

Switch to consumer interaction data

Moderate

DAUNOrubicin liposomal palifermin

Applies to: Vyxeos (cytarabine liposomal / daunorubicin liposomal) and palifermin

ADJUST DOSING INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.

MANAGEMENT: Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.

References

  1. (2004) "Product Information. Kepivance (palifermin)." Shire US Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer